Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3183)	6/3/1999 3:56:00 PM
From: Biomaven	Respond to of 10280

Has SEPR done any deals with company's like Inhale or Dura that have metered dose inhaler technology. They have a deal for a MDI with SkyePharma signed last year. SKYEY more recently signed a similar deal with Novartis for another asthma drug. Don't think the SEPR MDI is in the clinic yet. Peter

To: Vector1 who wrote (3183)	6/3/1999 4:28:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

See the user report on Yahoo #6106. Sounds real good to me.

To: Vector1 who wrote (3183)	6/3/1999 5:59:00 PM
From: BMcV	Respond to of 10280

>>Has SEPR done any deals with company's like Inhale or Dura that have metered dose inhaler technology.<< Besides the SkyePharma agreement that Peter mentioned, SEPR was also trying to develop delivery technology in house, although I'm guessing either it didn't work out, or was delayed, making the Skye deal necessary. Here's news from 1995: BW1201 MAY 11,1995 9:29 PACIFIC 12:29 EASTERN SEPRACOR TO ACQUIRE LEADING INHALATION TECHNOLOGY, FURTHER STRENGTHENING ASTHMA STRATEGY Business Editors REPEATING MARLBOROUGH, Mass.--(BUSINESS WIRE)--May 11, 1995--Sepracor Inc. (NASDAQ: SEPR) today announced that it has agreed to acquire the assets of New England Pharmaceuticals, Inc., a manufacturer and developer of delivery systems for respiratory and nonrespiratory drugs. Systems manufactured or under development include breath-actuated, metered-dose and dry-powder inhalers. Breath- actuated inhalation systems are emerging as a preferred vehicle to administer asthma compounds. "This acquisition provides Sepracor with technical capabilities in aerosol pharmaceutical science, further strengthening our asthma strategy and enabling other nonrespiratory opportunities," said Timothy J. Barberich, Sepracor's President and Chief Executive Officer. "Coupling R-albuterol and R,R-formoterol with this breath-actuated delivery technology is another significant advance in our effort to develop single-isomer b2-agonists as bronchodilators of choice," said David S. Barlow, Sepracor's General Manager, Pharmaceuticals. Sepracor recently announced results of an initial Phase II clinical trial studying albuterol and its isomers in mild asthmatics. This and other studies have indicated that the R-isomer is responsible for bronchodilation, the desired therapeutic effect, while the S-isomer can cause hyperreactivity and is metabolized more slowly than the R-isomer. The U.S. respiratory market of several billion dollars is expected to remain a fast-growing segment of the pharmaceutical industry. New England Pharmaceuticals was founded by John Armstrong, who also founded Armstrong Laboratories, subsequently purchased by Medeva plc; and Pharmasol, subsequently purchased by Fisons plc. Armstrong will become a consultant to Sepracor. Sepracor develops Improved Chemical Entities (ICE's) that are potentially enhanced forms of existing, widely sold pharmaceuticals. ICE's, which cover product opportunities with strong market potential, can be developed at less cost, time and risk than New Chemical Entities (NCEs). --30--rs/bos CONTACT: David P. Southwell Chief Financial Officer Sepracor Inc. or Jean M. Devine Director, Investor Relations Sepracor Inc. (508) 481-6700